All News

meeting.photo_.jpg

ACR20 - Day 2 Report

Jack Cush, MD

Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:

Read Article
For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA stratified by MRI and CRP status #ACR20 @steverheum_hall https://t.co/WI1vdMItUO https://t.co/JnvAyyClDu

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary

Links:

Peter Nash drpnash ( View Tweet)

Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

Dr. Antoni Chan synovialjoints ( View Tweet)

After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

Richard Conway RichardPAConway ( View Tweet)

We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients. Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow https://t.co/1SsL9qLJD3

Links:

k dao KDAO2011 ( View Tweet)

SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

Eric Dein ejdein1 ( View Tweet)

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

Janet Pope Janetbirdope ( View Tweet)
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Dr. Rachel Tate uptoTate ( View Tweet)
OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp8

Links:

k dao KDAO2011 ( View Tweet)

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

sheila RHEUMarampa ( View Tweet)
Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8
David Liew drdavidliew ( View Tweet)

Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj

Janet Pope Janetbirdope ( View Tweet)
FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z

sheila RHEUMarampa ( View Tweet)
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
This convinces me! #TNF inhibitors vs #JAKI great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow

Eric Dein ejdein1 ( View Tweet)

More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×